Clinical Trial: Metastatic Non-Familial Adenocarcinoma Maintenance Therapy With DZ-002: Heptamine Carboxymethine Dye Conjugate

U.S., Jan. 16 -- ClinicalTrials.gov registry received information related to the study (NCT07344220) titled 'Metastatic Non-Familial Adenocarcinoma Maintenance Therapy With DZ-002: Heptamine Carboxymethine Dye Conjugate' on Nov. 12, 2025.

Brief Summary: The goal of this clinical trial is to learn if drug DZ-002 works to treat adults with metastatic pancreatic adenocarcinoma. It will also learn about the safety of drug DZ-002. The main questions it aims to answer are:

* To determine the appropriate dose of DZ-002; and

* To assess the safety and efficacy of DZ-002.

Participants will receive one of three different doses of the study drug through an IV over a 4-hour period on Days 1, 8, 15, and 22 of a 4-week period, or cycle. During the st...